Cannabinoids, endocannabinoids, and related analogs in inflammation

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 109-119

  Burstein, Sumner H ^a   Zurier, Robert B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Ajulemic acid; Cannabinoid; Elmiric acid; Endocannabinoid; Inflammation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; ANANDAMIDE; CANNABICHROMENE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; CARYOPHYLLENE; CYCLOOXYGENASE 2 INHIBITOR; DEXANABINOL; ENDOCANNABINOID; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; LUTEOLIN; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; PALMIDROL; PLACEBO; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATAXIA; ATHEROSCLEROSIS; BRONCHOSPASM; CELIAC DISEASE; CLINICAL TRIAL; COLON CANCER; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; EVENING DOSAGE; FATTY ACID SYNTHESIS; FIBROMYALGIA; GLUTEN FREE DIET; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORNING DOSAGE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATHOGENESIS; PAW EDEMA; POSTOPERATIVE PAIN; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; TACHYCARDIA; VERTIGO; XEROSTOMIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; CANNABINOIDS; CANNABIS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; ENDOCANNABINOIDS; FIBROMYALGIA; GLYCINE; HUMANS; INFLAMMATION; MICE; PLANT OILS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 65549122582     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9084-5     Document Type: Review

References (122)

1. S. H. Burstein. The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential. Pharmacol. Ther. 82(1):87-96 (1999).
2. S. Burstein. The elmiric acids: Biologically active anandamide analogs. Neuropharmacology. 55:1259-1264 (2007).
3. S. Burstein. Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J. 7(1):E143-148 (2005).
4. R. B. Zurier. Prospects for cannabinoids as anti-inflammatory agents. J. Cell Biochem. 88(3):462-466 (2003).
5. J. Gertsch, M. Leonti, S. Raduner, I. Racz, J. Z. Chen, X. Q. Xie, K. H. Altmann, M. Karsak, and A. Zimmer. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U. S. A. 105(26):9099-9104 (2008).
6. T. W. Klein, and G. A. Cabral. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol. 1(1):50-64 (2006).
7. T. W. Klein. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5(5):400-411 (2005).
8. T. W. Klein, and C. A. Newton. Therapeutic potential of cannabinoid-based drugs. Adv. Exp. Med. Biol. 601:395-413 (2007).
9. J. P. Buchweitz, P. W. Karmaus, K. J. Williams, J. R. Harkema, and N. E. Kaminski. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 83(3):785-796 (2008).
10. C. Fimiani, T. Liberty, A. J. Aquirre, I. Amin, N. Ali, and G. B. Stefano. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat. 57(1):23-34 (1999).
11. P. F. Sumariwalla, R. Gallily, S. Tchilibon, E. Fride, R. Mechoulam, and M. Feldmann. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50(3):985-998 (2004).
12. B. Costa, M. Colleoni, S. Conti, D. Parolaro, C. Franke, A. E. Trovato, and G. Giagnoni. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch. Pharmacol. 369(3):294-299 (2004).
13. B. Costa, A. E. Trovato, F. Comelli, G. Giagnoni, and M. Colleoni. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur. J. Pharmacol. 556(1-3):75-83 (2007).
14. G. Esposito, D. De Filippis, M. C. Maiuri, D. De Stefano, R. Carnuccio, and T. Iuvone. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci. Lett. 399(1-2):91-95 (2006).
15. G. Esposito, C. Scuderi, C. Savani, L. Steardo Jr., D. De Filippis, P. Cottone, T. Iuvone, V. Cuomo, and L. Steardo. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151(8):1272-1279 (2007).
16. E. D. Giudice, L. Rinaldi, M. Passarotto, F. Facchinetti, A. D'Arrigo, A. Guiotto, M. D. Carbonare, L. Battistin, and A. Leon. Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J. Leukoc. Biol. 81(6):1512-1522 (2007).
17. A. Thomas, G. L. Baillie, A. M. Phillips, R. K. Razdan, R. A. Ross, and R. G. Pertwee. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150(5):613-623 (2007).
18. D. McHugh, C. Tanner, R. Mechoulam, R. G. Pertwee, and R. A. Ross. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB2. Mol. Pharmacol. 73(2):441-450 (2008).
19. R. Capasso, F. Borrelli, G. Aviello, B. Romano, C. Scalisi, F. Capasso, and A. A. Izzo. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Pharmacol. 154(5):1001-1008 (2008).
20. S. Ben-Shabat, L. O. Hanus, G. Katzavian, and R. Gallily. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem. 49(3):1113-1117 (2006).
21. M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, J. W. Huffman, A. Csiszar, Z. Ungvari, K. Mackie, S. Chatterjee, and P. Pacher. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. 293(4):H2210-2218 (2007).
22. E. Russo, and G. W. Guy. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses. 66(2):234-246 (2006).
23. D. R. Blake, P. Robson, M. Ho, R. W. Jubb, and C. S. McCabe. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford, England). 45(1):50-52 (2006).
24. S. H. Burstein, M. Karst, U. Schneider, and R. B. Zurier. Ajulemic acid: a novel cannabinoid produces analgesia without a "high". Life Sci. 75(12):1513-1522 (2004).
25. J. L. Wiley. Ajulemic acid. IDrugs. 8(12):1002-1011 (2005).
26. R. B. Zurier, R. G. Rossetti, J. H. Lane, J. M. Goldberg, S. A. Hunter, and S. H. Burstein. Dimethylheptyl-THC-11 oic acid: A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 41(1):163-170 (1998).
27. D. R. Johnson, J. A. Stebulis, R. G. Rossetti, S. H. Burstein, and R. B. Zurier. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell Biochem. 100(1):184-190 (2007).
28. J. Parker, F. Atez, R. G. Rossetti, A. Skulas, R. Patel, and R. B. Zurier. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol. Int. 28(7):631-635 (2008).
29. J. A. Stebulis, D. R. Johnson, R. G. Rossetti, S. H. Burstein, and R. B. Zurier. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 83(19-20):666-670 (2008) doi: 10.1016/j.lfs.2008.09.004.
30. R. B. Zurier, Y. -P. Sun, K. L. George, J. A. Stebulis, R. G. Rossetti, A. Skulas, E. Judge, C. N. Serhan. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A 4. FASEB J. (2009) doi: 10.1096/ fj.08-118323.
31. A. Dyson, M. Peacock, A. Chen, J. P. Courade, M. Yaqoob, A. Groarke, C. Brain, Y. Loong, and A. Fox. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain. 116(1-2):129-137 (2005).
32. A. Fox, and S. Bevan. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert. Opin. Investig. Drugs. 14(6):695-703 (2005).
33. R. E. Vann, C. D. Cook, B. R. Martin, and J. L. Wiley. Cannabimimetic properties of ajulemic acid. J. Pharmacol. Exp. Ther. 320(2):678-686 (2007).
34. V. A. Mitchell, S. Aslan, R. Safaei, and C. W. Vaughan. Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neurosci. Lett. 382(3):231-235 (2005).
35. M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy, and U. Schneider. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. JAMA. 290(13):1757-1762 (2003).
36. A. L. Ambrosio, S. M. Dias, I. Polikarpov, R. B. Zurier, S. H. Burstein, and R. C. Garratt. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282(25):18625-18633 (2007).
37. J. Liu, H. Li, S. H. Burstein, R. B. Zurier, and J. D. Chen. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63(5):983-992 (2003).
38. A. L. Ambrosio, S. M. Dias, I. Polikarpov, R. B. Zurier, S. H. Burstein, and R. C. Garratt. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor {gamma}. J. Biol. Chem. 282(25):18625-18633 (2007).
39. S. L. Teitelbaum, and F. P. Ross. Genetic regulation of osteoclast development and function. Nat. Rev. 4(8):638-649 (2003).
40. K. L. George, L. H. Saltman, G. S. Stein, J. B. Lian, and R. B. Zurier. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J. Cell Physiol. 214(3):714-720 (2008).
41. R. Q. Skrabek, L. Galimova, K. Ethans, and D. Perry. Nabilone for the treatment of pain in fibromyalgia. J. Pain. 9(2):164-173 (2008).
42. P. Beaulieu, and M. Ware. Reassessment of the role of cannabinoids in the management of pain. Curr. Opin. Anaesthesiol. 20(5):473-477 (2007).
43. P. Beaulieu. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can. J. Anaesth. 53(8):769-775 (2006).
44. C. A. Lunn, J. S. Fine, A. Rojas-Triana, J. V. Jackson, X. Fan, T. T. Kung, W. Gonsiorek, M. A. Schwarz, B. Lavey, J. A. Kozlowski, S. K. Narula, D. J. Lundell, R. W. Hipkin, and L. A. Bober. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 316(2):780-788 (2006).
45. E. Selvi, S. Lorenzini, E. Garcia-Gonzalez, R. Maggio, P. E. Lazzerini, P. L. Capecchi, E. Balistreri, A. Spreafico, S. Niccolini, G. Pompella, M. R. Natale, F. Guideri, F. Laghi Pasini, M. Galeazzi, and R. Marcolongo. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26(4):574-581 (2008).
46. E. C. Mbvundula, R. A. Bunning, and K. D. Rainsford. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 69(4):635-640 (2005).
47. L. Giannini, S. Nistri, R. Mastroianni, L. Cinci, A. Vannacci, C. Mariottini, M. B. Passani, P. F. Mannaioni, D. Bani, and E. Masini. Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. J. Cell. Mol. Med. 12(6A):2381-2394 (2008).
48. J. C. Ashton, J. L. Wright, J. M. McPartland, and J. D. Tyndall. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr. Med. Chem. 15(14):1428-1443 (2008).
49. D. G. Deutsch, N. Ueda, and S. Yamamoto. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3):201-210 (2002).
50. A. Giuffrida, M. Beltramo, and D. Piomelli. Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298(1):7-14 (2001).
51. R. A. Puffenbarger. Molecular biology of the enzymes that degrade endocannabinoids. Curr. Drug Targets CNS Neurol. Disord. 4(6):625-631 (2005).
52. N. Ueda, K. Tsuboi, and D. M. Lambert. A second N-acylethanolamine hydrolase in mammalian tissues. Neuropharmacology. 48(8):1079-1085 (2005).
53. A. Giuffrida, and D. Piomelli. The endocannabinoid system: A physiological perspective on its role in psychomotor control. Chem. Phys. Lipids. 108(1-2):151-158 (2000).
54. H. Schuel, L. J. Burkman, J. Lippes, K. Crickard, E. Forester, D. Piomelli, and A. Giuffrida. N-Acylethanolamines in human reproductive fluids. Chem. Phys. Lipids. 121(1-2):211-227 (2002).
55. G. Kunos, Z. Jarai, K. Varga, J. Liu, L. Wang, and J. A. Wagner. Cardiovascular effects of endocannabinoids - the plot thickens. Prostaglandins Other Lipid Mediat. 61 (1-2):71-84 (2000).
56. A. H. Lichtman, S. A. Varvel, and B. R. Martin. Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3):269-285 (2002).
57. M. Maccarrone, K. Falciglia, M. Di Rienzo, and A. Finazzi-Agro. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3):309-317 (2002).
58. E. Murillo-Rodríguez, M. Sánchez-Alavez, L. Navarro, D. Martínez-González, R. Drucker-Colín, and O. Prospéro-García. Anandamide modulates sleep and memory in rats. Brain Res. 812(1-2):270-274 (1998).
59. D. Parolaro, P. Massi, T. Rubino, and E. Monti. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3):319-332 (2002).
60. J. M. Walker, and S. M. Huang. Endocannabinoids in pain modulation. Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3):235-242 (2002).
61. A. C. Howlett, and S. Mukhopadhyay. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids. 108(1-2):53-70 (2000).
62. H. B. Bradshaw, N. Rimmerman, J. F. Krey, and J. M. Walker. Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291(2):R349-358(2006).
63. H. B. Bradshaw, and J. M. Walker. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144(4):459-465 (2005).
64. L. De Petrocellis, D. Melck, T. Bisogno, and V. Di Marzo. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem. Phys. Lipids. 108(1-2):191-209 (2000).
65. H. Schwarz, F. J. Blanco, and M. Lotz. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55(1):107-115 (1994).
66. M. Maccarrone, T. Lorenzon, M. Bari, G. Melino, and A. Finazzi-Agro. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275(41):31938-31945 (2000).
67. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator activated receptor{gamma} independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70(1):101-111 (2006).
68. B. L. Kaplan, Y. Ouyang, A. Herring, S. S. Yea, R. Razdan, and N. E. Kaminski. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2′-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicol. Appl. Pharmacol. 205(2):107-115 (2005).
69. B. L. Kaplan, Y. Ouyang, C. E. Rockwell, G. K. Rao, and N. E. Kaminski. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J. Leukoc. Biol. 77(6):966-974 (2005).
70. C. E. Rockwell, and N. E. Kaminski. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 311(2):683-690 (2004).
71. J. Li, N. E. Kaminski, and D. H. Wang. Anandamide-induced depressor effect in spontaneously hypertensive rats: Role of the vanilloid receptor. Hypertension. 41(3 Pt 2):757-762 (2003).
72. D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, G. Martino, and M. Maccarrone. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 130(Pt 10):2543-2553 (2007).
73. D. Centonze, A. Finazzi-Agro, G. Bernardi, and M. Maccarrone. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28(4):180-187 (2007).
74. J. LoVerme, G. La Rana, R. Russo, A. Calignano, and D. Piomelli. The search for the palmitoylethanolamide receptor. Life Sci. 77(14):1685-1698 (2005).
75. G. Re, R. Barbero, A. Miolo, and V. Di Marzo. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet. J. 173 (1):21-30 (2007).
76. M. Dalle Carbonare, E. Del Giudice, A. Stecca, D. Colavito, M. Fabris, A. D'Arrigo, D. Bernardini, M. Dam, and A. Leon. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: A neglected story. J. Neuroendocrinol. 20(Suppl 1):26-34 (2008).
77. L. E. Wise, R. Cannavacciulo, B. F. Cravatt, B. F. Martin, and A. H. Lichtman. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology. 54(1):181-188 (2008).
78. G. D'Argenio, S. Petrosino, C. Gianfrani, M. Valenti, G. Scaglione, I. Grandone, S. Nigam, I. Sorrentini, G. Mazzarella, and V. Di Marzo. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med. (Berlin, Germany). 85(5):523-530 (2007).
79. Y. Avraham, I. Magen, O. Zolotarev, L. Vorobiav, A. Nachmias, O. Pappo, Y. Ilan, E. M. Berry, and Z. Ackerman. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease. Prostaglandins Leukot. Essent. Fatty Acids. 79(1-2):35-40 (2008).
80. F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory, B. F. Cravatt, G. L. Ferri, A. Sibaev, M. Storr, and B. Lutz. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113(8):1202-1209 (2004).
81. Y. Nakajima, Y. Furuichi, K. K. Biswas, T. Hashiguchi, K. Kawahara, K. Yamaji, T. Uchimura, Y. Izumi, and I. Maruyama. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 580(2):613-619 (2006).
82. J. Zhang, and C. Chen. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283(33):22601-22611 (2008).
83. R. Sancho, M. A. Calzado, V. Di Marzo, G. Appendino, and E. Munoz. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 63(2):429-438 (2003).
84. S. M. Huang, T. Bisogno, T. J. Petros, S. Y. Chang, P. A. Zavitsanos, R. E. Zipkin, R. Sivakumar, A. Coop, D. Y. Maeda, L. De Petrocellis, S. Burstein, V. Di Marzo, and J. M. Walker. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 276(46):42639-42644 (2001).
85. S. M. A. Burstein, W. Pearson, T. Rooney, B. Yagen, R. Zipkin, A. Zurier. Symposium on Cannabinoids, pp 31 (1997).
86. J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sanudo-Pena. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 96(21):12198-12203 (1999).
87. R. G. Pertwee. Cannabinoid receptors and pain. Prog. Neurobiol. 63(5):569-611 (2001).
88. R. G. Pertwee. The ring test: A quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br. J. Pharmacol. 46(4):753-763 (1972).
89. T. Sheskin, L. Hanus, J. Slager, Z. Vogel, and R. Mechoulam. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40(5):659-667 (1997).
90. C. R. Hiley, and S. S. Kaup. GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152(5):559-561 (2007).
91. D. G. Johns, D. J. Behm, D. J. Walker, Z. Ao, E. M. Shapland, D. A. Daniels, M. Riddick, S. Dowell, P. C. Staton, P. Green, U. Shabon, W. Bao, N. Aiyar, T. L. Yue, A. J. Brown, A. D. Morrison, and S. A. Douglas. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152(5):825-831 (2007).
92. S. Oka, K. Nakajima, A. Yamashita, S. Kishimoto, and T. Sugiura. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362(4):928-934 (2007).
93. A. L. Wiles, R. J. Pearlman, M. Rosvall, K. R. Aubrey, and R. J. Vandenberg. N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. J. Neurochem. 99: 781-786 (2006).
94. Z. Yang, K. R. Aubrey, I. Alroy, R. J. Harvey, R. J. Vandenberg, and J. W. Lynch. Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem. Pharmacol. 76(8):1014-1023 (2008). 1014-1023 (2008).
95. L. C. Samuelson, L. J. Swanberg, and I. Gantz. Mapping of the novel G protein-coupled receptor Gpr18 to distal mouse chromosome 14. Mamm. Genome. 7(12):920-921 (1996).
96. M. Kohno, H. Hasegawa, A. Inoue, M. Muraoka, T. Miyazaki, K. Oka, and M. Yasukawa. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun. 347(3):827-832 (2006).
97. Y. Oh da, J. M. Yoon, M. J. Moon, J. I. Hwang, H. Choe, J. Y. Lee, J. I. Kim, S. Kim, H. Rhim, D. K. O'Dell, J. M. Walker, H. S. Na, M. G. Lee, H. B. Kwon, K. Kim, and J. Y. Seong. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J. Biol. Chem. 283(30):21054-21064 (2008).
98. J. J. Prusakiewicz, P. J. Kingsley, K. R. Kozak, and L. J. Marnett. Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. Biochem. Biophys. Res. Commun. 296(3):612-617 (2002).
99. H. B. Bradshaw, E. Verfring, J. A. Jahnsen, O'Dell, S. Burstein, M. J. Walker. ICRS Symposium on Cannabinoids, Clearwater, FL, (2005).
100. G. Milman, Y. Maor, S. Abu-Lafi, M. Horowitz, R. Gallily, S. Batkai, F. M. Mo, L. Offertaler, P. Pacher, G. Kunos, and R. Mechoulam. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl. Acad. Sci. U. S. A. 103(7):2428-2433 (2006).
101. J. C. Sipe, N. Arbour, A. Gerber, and E. Beutler. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders. J. Leukoc. Biol. 78(1):231-238 (2005).
102. S. H. Burstein, J. K. Adams, H. B. Bradshaw, C. Fraioli, R. G. Rossetti, R. A. Salmonsen, J. W. Shaw, J. M. Walker, R. E. Zipkin, and R. B. Zurier. Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg. Med. Chem. 15(10):3345-3355 (2007).
103. B. F. Cravatt, K. Demarest, M. P. Patricelli, M. H. Bracey, D. K. Giang, B. R. Martin, and A. H. Lichtman. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 98(16):9371-9376 (2001).
104. M. Cascio, A. Minassi, A. Ligresti, G. Appendino, S. Burstein, and V. Di Marzo. A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 314(1):192-196 (2004).
105. L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112(6):945-955 (2003).
106. S. R. Smith, G. Denhardt, and C. Terminelli. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur. J. Pharmacol. 432(1):107-119 (2001).
107. C. A. Audette, and S. Burstein. Inhibition of leukocyte adhesion by the in vivo and in vitro administration of cannabinoids. Life Sci. 47(9):753-759 (1990).
108. S. H. Burstein, C. A. Audette, S. A. Doyle, K. Hull, S. A. Hunter, and V. Latham. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J. Pharmacol. Exp. Ther. 251(2):531-535 (1989).
109. S. Burstein, S. A. Hunter, K. Ozman, and L. Renzulli. Prostaglandins and cannabis - XIII. Cannabinoid-induced elevation of lipoxygenase products in mouse peritoneal macrophages. Biochem. Pharmacol. 33(16):2653-2656 (1984).
110. S. Burstein. Cannabinoid induced changes in eicosanoid synthesis by mouse peritoneal cells. Adv. Exp. Med. Biol. 288: 107-112 (1991).
111. R. Succar, V. A. Mitchell, and C. W. Vaughan. Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol. Pain. 3(1):24 (2007).
112. L. A. Vuong, V. A. Mitchell, and C. W. Vaughan. Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology. 54(1):189-193 (2008).
113. S. Burstein, and R. Salmonsen. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg. Med. Chem. 16(22):9644-9651 (2008).
114. M. L. Barrett, D. Gordon, and F. J. Evans. Isolation from Cannabis sativa L. of cannflavin - a novel inhibitor of prostaglandin production. Biochem. Pharmacol. 34(11):2019-2024 (1985).
115. M. L. Barrett, A. M. Scutt, and F. J. Evans. Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia. 42(4):452-453 (1986).
116. R. D. Sofia, S. D. Nalepa, H. B. Vassar, and L. C. Knobloch. Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci. 15(2):251-260 (1974).
117. S. Burstein, C. Varanelli, and L. T. Slade. Prostaglandins and cannabis - III. Inhibition of biosynthesis by essential oil components of marihuana. Biochem. Pharmacol. 24(9):1053-1054 (1975).
118. R. K. Razdan. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38(2):75-149 (1986).
119. S. Hougee, A. Sanders, J. Faber, Y. M. Graus, W. B. van den Berg, J. Garssen, H. F. Smit, and M. A. Hoijer. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem. Pharmacol. 69(2):241-248 (2005).
120. A. M. Lehane, and K. J. Saliba. Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite. BMC Res. Notes. 1: 26 (2008).
121. P. Ashokkumar, and G. Sudhandiran. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed. Pharmacother. 62(9):590-597 (2008).
122. L. Hui-Lin. The origin and use of cannabis in Eastern Asia. In V. Rubin (ed.), Cannabis and Culture, Mouton, The Hague, 1975.